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it not be appropriate to use beta-blocker therapy in addition to
implantable devices to reduce the risk of ventricular tachy-
fibrillation in light of the published data demonstrating reduced
mortality as well as sudden death in those receiving beta-blocker
intervention?
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REPLY
We read Dr. Baird’s comments with much interest. He raised two
important issues regarding our findings (1). First, with respect to
the effect of possible proarrhythmia from antiarrhythmic drugs, it
is certainly plausible that some of the deaths may have been related
to drug proarrhythmia. Indeed, one death (patient no. 2, Table 1)
was attributed to potential adverse drug (tocainide and encainide)
effect; however, whether or not other deaths were related to drug
proarrhythmia could not be ascertained from our data. Second, the
use of beta-blocker therapy certainly should be encouraged in the
proper settings. The benefit of beta-blocker therapy is undisputed
in patients at risk for arrhythmic events (e.g., after myocardial
infarction) and may, in fact, be beneficial as single or adjuvant
therapy in select patients who have had symptomatic, sustained
ventricular arrhythmias (2,3).
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Chlamydia pneumoniae in Redo and First-
Time Coronary Artery Bypass Graft Surgery
In their recent study, Wong et al. (1) tried to determine if
Chlamydia pneumoniae was more prevalent in atherosclerotic blood
vessels as compared with normal blood vessels of patients requiring
redo and first-time coronary artery bypass graft surgery (CABG).
Using a very detailed methodologic process, they concluded that
C. pneumoniae is not an important factor in graft failure. This very
important question seems not to be definitively answered by the
authors. First, the authors did not explain when the graft failed
among the elective patients who had a redone CABG, knowing
that a dramatic proportion of these occlusions occur soon after the
operation and are attributed to technical reasons rather than
atherosclerosis progression, as the authors hypothesized, even in
asymptomatic patients. Second, whether or not the organism is
found in plaques does not alter the basis of the infective hypothesis
and atherosclerosis. That is the role of immune system activation
in the presence of bacterial components (2,3). Finally, the authors
considered that a few recently published, small clinical studies
using antibiotics in patients with coronary artery disease were trials
without a clear benefit. It is important to remember that these pilot
studies are testing clinical, serologic and immunologic hypotheses,
irrespective of the efficacy or safety of one particular compound (4).
These results should not be used to support part of the findings of
one single study.
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REPLY
Evidence that Chlamydia pneumoniae is associated with atheroscle-
rosis has come from serological and pathological studies. Patho-
logical studies have reported that C. pneumoniae is more common
in atherosclerotic vessels as compared with normal blood vessels.
This has been put forward as evidence that C. pneumoniae may be
a cause of atherosclerosis. However, few studies have used ade-
quate control data (1). In our study of patients needing first-time
and redo coronary artery bypass graft surgery (CABG), we exam-
ined occluded venous grafts, endarterectomy specimens from
native coronary arteries, new saphenous vein (SV) grafts and new
left internal mammary artery (LIMA) grafts (2). Graft failure is
less common with LIMA than with SV grafts, but we found that
the prevalence of C. pneumoniae was significantly greater in new
LIMA than in new SV grafts. Also C. pneumoniae was just as
prevalent in new LIMA grafts as in failed grafts and diseased
native vessels. Therefore, we concluded that C. pneumoniae was
unlikely to be important in graft failure.
Gurfinkel implies that atherosclerosis may not have been a cause
of graft failure in our study. In our unit, it is not our experience that
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